Cognitive function in early clinical phase Huntington disease after rivastigmine treatment

Psychiatria Danubina

Volumn 26, Issue 3, 2014, Pages 239-248

  Šešok, Sanja ^a   Bolle, Nika ^a   Kobal, Jan ^a   Bucik, Valentin ^b   Vodušek, David B ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cognitive function; Huntington disease; Neuropsychology; Rivastigmine

Indexed keywords

ALPRAZOLAM; CITALOPRAM; OLANZAPINE; PLACEBO; QUETIAPINE; RIVASTIGMINE; SERTRALINE; CARBAMIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT;

ADULT; ARTICLE; CALIFORNIA VERBAL LEARNING TEST; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPREHENSIVE TRAIL MAKING TEST; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; MALE; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REY COMPLEX FIGURE TEST; RUFF FIGURAL FLUENCY TEST; STROOP TEST; SYMBOL DIGIT MODALITIES TEST; UNIFIED HUNTINGTON DISEASE RATING SCALE; VERBAL FLUENCY; CONTROLLED CLINICAL TRIAL; DEMENTIA; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; SLOVENIA; STATISTICS;

ADULT; COGNITION DISORDERS; DEMENTIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PSYCHOMETRICS; SLOVENIA;

EID: 84907167457     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bachoud-Levi AC, Maison P, Bartolomeo P, Boisse MF, Dalla Barba G, Ergis A, et al.: Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 2001; 56:1052-1058.
2. Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L: Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997; 120:2207-17.
3. Baldo JV, Delis D, Kramer J, Shimamura AP: Memory performance on the California Verbal Learning Test-II: findings from patients with focal frontal lesions. Journal of the International Neuropsychological Society 2002; 8:539-546.
4. Benton AL, Hamsher KS, Sivan AB: Multilingual Aphasia Examination (MAE): Manual. Psychological Assessment Resources, Odessa, 1994.
5. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006; 25.
6. Craufurd D, Snowden JS: Neuropsychological and neuropsychiatric aspects of Huntington's disease. In P Harper, G Bates & L Jones (eds): Huntington's disease 3rd edition, 62-94. Oxford: Oxford University Press, 2002.
7. Culbertson WC, Zillmer EA: Tower of London-Drexel University (TOLdx), 2nd edition: Technical Manual. Multi-Health Systems Inc, Tonawanda, 2005.
8. Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning Test-second edition (CVLT-II): Manual. The psychological corporation, Hartcourt Assessment Company, San Antonio, 2000.
9. De Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P: Two years Follow up of Rivastigmine Follow-up in Huntington disease. Clinical Neuropharmacology 2007; 30:43-46.
10. De Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM: Effects of Rivastigmine on motor and cognitive impairment in Huntington's disease. Movement Disorders 2004; 19:1516-18.
11. Doraiswamy PM, Krishnan KRR, Anand R, Sohn H, Danyluk J, Hartman RD, Veach J: Long-term effects of rivastigmine in moderately severe Alzheimer's disease. Does early initiation of therapy offer sustained benefits? Progress in Neuro-Psychophatmacology and Biological Psychiatry 2002; 26:705-712.
12. Duke LM, Kaszniak AW: Executive Control functions in degenerative dementias: A comparative review. Neuropsychology Review 2000; 10:75-99.
13. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, et al.: Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine 2004; 351:2509-2518.
14. Folstein M, Folstein S, McHugh P, Fanijang G: Minimental state examination: Clinical guide. Psychological Assessment Resources, Florida, 2001.
15. Golden CJ: Stroop Color and Word Test: A manual for clinical and experimental uses. Stoelting Company, Illinois, 1978.
16. Hahn-Barma V, Dewer B, Durr A, Dode C, Feingold J, Pillon B, et al.: Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. Journal of Neurology, Neurosurgery & Psychiatry 1998; 64:172-177.
17. Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN, et al.: Profile of cognitive progression in early Huntington's disease. Neurology 2003; 61:1702-6.
18. Jensen AR: Scoring the Stroop test. Acta Psychologia 1965; 24:398-408.
19. Josefson D: Molecular basis underlying Huntington's chorea found. BMJ 1997; 315:445-448.
20. Kanazawa I, Sasaki H, Muramoto O, Matsushita M, Mizutani T, Iwabuchi K, et al.: Studies on neurotransmitter markers and striatal neuron density in Huntington's disease and dentatorubropallidoluysian atrophy. Journal of Neurological Science 1985; 70:151-165.
21. Kirkwood SC, Siemers E, Bond C, Conneally M, Christian JC, Foroud T: Confirmation of subtle motor changes among presymptomatic carriers of the Huntington Disease Gene. Archives of Neurology 2000; 57:1040-1044.
22. Kirkwood SC, Siemers E, Hodes ME, Conneally PM, Christian JC, Foroud T: Subtle changes among presymptomatic carriers of the Huntington's disease gene. Journal of Neurology, Neurosurgery & Psyciatry 2000; 69:773-779.
23. Kirkwood SC, Siemers E, Stout JC, Hodes ME, Conneally PM, Christian JC, et al.: Longitudinal cognitive and motor changes among presymptomatic Huntington's disease gene carriers. Archives of Neurology 1999; 56:563-8.
24. Kumar P, Kumar A: Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: Possible behavioural, biochemical and cellular alterations. European Journal of Pharmacology 2009; 615:91-101.
25. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, french-Constant C, Rubinsztein DC, et al.: Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998; 121:1329-41.
26. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW: Executive and mnemonic functions in early Huntington's disease. Brain 1996; 119:1633-1645.
27. Lawrence AD, Sahakian BJ, Robbins TW: Cognitive functions and corticostriatal circuits: insights from Huntington's disease. Trends in Cognitive Sciences 1998; 10.
28. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R: Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation. Journal of Neurology 2004; 251:935-942.
29. Lezak MD: Neuropsychological assessment 4th ed. Oxford University Press, New York, 2004.
30. Meyers JE, Meyers KR: Rey Complex Figure Test and Recognition Trial (RCFT): Professional Manual. Psychological Assessment Resources, Odessa, 1995.
31. Montoya A, Price BH, Menear M, Lepage M: Brain imaging and cognitive dysfunctions in Huntington's disease. Journal of Psychiatry Neuroscience 2006; 1:21-29.
32. Paulsen J S: Early Detection of Huntington's disease. Future Neurology 2010; 1:85-104.
33. Paulsen J S: Cognitive Impairment in Huntington Disease: Diagnosis and Follow-up. Current Neurology & Neuroscience Reports 2011; 11:474-483.
34. Reading PJ, Luce AK, McKeith IG: Rivastigmine in treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement disorders 2001; 16:1171-1174.
35. Reynolds CR: Comprehensive Trail-Making Test: Examiner's manual. Pro-ed, An International Publisher, Austin, 2002.
36. Roesler M, Anand R, Cicin-Sain A: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318:633-638.
37. Ross AC, Margolis RL: Huntington's disease. Journal of Neuroscience Research 2001; 1:142-152.
38. Rot U, Kobal J, Sever A, Pirtošek Z, Mesec A: Rivastigmine in the Follow-up of Huntington's disease. European Journal of Neurology 2002; 9:687-702.
39. Ruff RM: Ruff Figural Fluency Test: Professional Manual. Psychological Assessment Resources, Odessa, 1996.
40. Schmitt FA, Aarsland: Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADASCog Items. American Journal of Alzheimer's Disease and Other Dementias 2010; 25:407-413.
41. Shimamura AP: The role of the prefrontal cortex in dynamic filtering. Psychobiology 2000; 28:207-218.
42. Smith A: Symbol Digit Modalities Test: Manual. Western psychological services, Los Angeles, 2002.
43. Snyder PJ, Nussbaum PD: Clinical Neuropsychology: A pocket handbook for assessment. American Psychological Association, Washington, DC, 1998.
44. Spires TL, Hannan AJ: Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Journal 2005; 272:2347-2361.
45. Spokes EG: Neurochemical alterations in Huntington's chorea: a study on post-mortem brain tissue. Brain 1980; 103:179-210.
46. Van Raamsdonk JM, Hayden MR, Leavitt BR: Experimental models of Huntington's disease. Drug discovery Today: Disease Models 2005; 4:291-97.
47. Weintraub D, Somogyi M, Meng X: Rivastigmine in Alzheimer's Disease and Parkinson's Disease Dementia: An ADAS-Cog Factor Analysis. American Journal of Alzheimer's Disease and Other Dementias 2011; 26:443-449.
48. Wheeler MA, Stuss DT, Tulving E: Frontal lobe damage produces episodic memory impairment. Journal of the International Neuropsychological Society 1995; 1:525-536.
49. Witjes-Ane MN, Vegter-van der Vlis M, van Vugt JP, Lanser JB, Hermans J, Zwinderman AH, et al.: Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study. Journal of Neuropsychiatry & Clinical Neurosciences 2003; 15:7-16.
50. Woodford HJ, George J: Cognitive assessment in the elderly: a review of clinical methods. QJM: An International Journal of Medicine 2007; 100:469-484.